Unplanned pregnancy in an HIV positive woman undergoing alectinib treatment for metastatic non-small-cell lung carcinoma

Séverine Carlier, Luciano Carestia, Jean Christophe Marot, Grégoire Wieërs

    Résultats de recherche: Contribution à un journal/une revueArticleRevue par des pairs

    Résumé

    We report an unplanned pregnancy in an HIV-positive woman in her 20s who was undergoing treatment for 6 months with alectinib (Alecensa) for stage IV non-small-cell lung carcinoma. Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitor alectinib, a molecule that inhibits proteins involved in tumour cell growth, is the recommended first-line treatment option in case of ALK mutation. Although the patient was informed of the need for definitive contraception, she became pregnant during the treatment with alectinib. A complete tumour response was observed at the time the pregnancy was discovered. Treatment discontinuation was proposed as the patient wanted to keep the pregnancy. Alectinib was temporarily stopped throughout the remaining pregnancy period inline with the patient's wishes. The pregnancy was uncomplicated. She delivered a healthy female baby vaginally, with treatment being resumed after delivery. After 34 follow-up months, the patient remained in oncological remission and the child's physical development is normal.

    langue originaleAnglais
    Numéro d'articlee247530
    journalBMJ Case Reports
    Volume15
    Numéro de publication7
    Les DOIs
    Etat de la publicationPublié - 1 juil. 2022

    Empreinte digitale

    Examiner les sujets de recherche de « Unplanned pregnancy in an HIV positive woman undergoing alectinib treatment for metastatic non-small-cell lung carcinoma ». Ensemble, ils forment une empreinte digitale unique.

    Contient cette citation